Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema

Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psorias...

Full description

Bibliographic Details
Main Authors: Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza
Format: Article
Language:English
Published: PAGEPress Publications 2022-10-01
Series:Dermatology Reports
Subjects:
Psoriasis, Eczema, Tildrakizumab
Online Access:https://www.pagepress.org/journals/index.php/dr/article/view/9447

Internet

https://www.pagepress.org/journals/index.php/dr/article/view/9447

Similar Items